Skip to main content

Table 1 Potential financial burden of CM patients at different disease stages from diagnosis up to 3 years of follow up under the SUS perspective

From: Cutaneous melanoma: cost of illness under Brazilian health system perspectives

Stage

Outpatient visit office

Laboratory exam

Imaging exam

Surgery/ pathological analysis

Cancer Drugs

TOTAL

(SUS)

(R$a)

%

(R$)

%

(R$)

%

(R$)

%

(R$)

%

(R$)

0

75

21%

0

0%

0

0%

283

79%

0

0%

359 ± 35

IA

116

1.9%

158

2.5%

2574

41.4%

3269

52.6%

99

1.6%

6218 ± 621

IB

119

1.5%

179

3%

3043

37.7%

4245

52.5%

432

5.4%

8022 ± 802

II

129

1.4%

257

2.7%

3147

33.6%

4245

45.4%

1,6

16.9%

9365 ± 936

rIII

134

1.1%

583

4.7%

3145

25.6%

2861

23.3%

5,6

45.3%

12,285 ± 1228

unIII+IV

85

1.1%

419

5.2%

6865

85.1%

701

8.6%

0

0%

8070 ± 807

  1. aBrazilian currency: Reais (R$), R$1,0 = USD0,191,898;
  2. Costs estimated by the SIGTAP table according to medical procedures most commonly applied